113 related articles for article (PubMed ID: 21958854)
1. Comparing the intracellular fate of components within a noncovalent streptavidin nanoparticle with covalent conjugation.
Liu Y; Cheng D; Liu X; Liu G; Dou S; Xiao N; Chen L; Rusckowski M; Hnatowich DJ
Nucl Med Biol; 2012 Jan; 39(1):101-7. PubMed ID: 21958854
[TBL] [Abstract][Full Text] [Related]
2. Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111In.
Liu X; Wang Y; Nakamura K; Kawauchi S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ
J Nucl Med; 2009 Apr; 50(4):582-90. PubMed ID: 19289423
[TBL] [Abstract][Full Text] [Related]
3. Auger-mediated cytotoxicity of cancer cells in culture by an 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle.
Liu X; Nakamura K; Wang Y; Cheng D; Liang M; Xiao N; Chen L; Rusckowski M; Hnatowich DJ
J Biomed Nanotechnol; 2010 Apr; 6(2):153-7. PubMed ID: 20738069
[TBL] [Abstract][Full Text] [Related]
4. Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery.
Liu X; Wang Y; Nakamura K; Kubo A; Hnatowich DJ
Cancer Gene Ther; 2008 Feb; 15(2):126-32. PubMed ID: 18084241
[TBL] [Abstract][Full Text] [Related]
5. Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture.
Wang Y; Nakamura K; Liu X; Kitamura N; Kubo A; Hnatowich DJ
Bioconjug Chem; 2007; 18(4):1338-43. PubMed ID: 17605463
[TBL] [Abstract][Full Text] [Related]
6. A nanoparticle for tumor targeted delivery of oligomers.
Liu X; Wang Y; Hnatowich DJ
Methods Mol Biol; 2011; 764():91-105. PubMed ID: 21748635
[TBL] [Abstract][Full Text] [Related]
7. Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle.
Wang Y; Liu X; Chen L; Cheng D; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2009 Dec; 36(12):1977-86. PubMed ID: 19572130
[TBL] [Abstract][Full Text] [Related]
8. In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles.
Wang Y; Liu X; Nakamura K; Chen L; Rusckowski M; Hnatowich DJ
Cancer Biother Radiopharm; 2009 Oct; 24(5):573-8. PubMed ID: 19877887
[TBL] [Abstract][Full Text] [Related]
9. Her2/neu small interfering RNA delivered in culture by a streptavidin nanoparticle.
Liu X; Nakamura K; Cheng D; Peng C; Xiao N; Liu Y; Chen L; Rusckowski M; Hnatowich DJ
Curr Drug Deliv; 2012 Jul; 9(4):431-6. PubMed ID: 22520071
[TBL] [Abstract][Full Text] [Related]
10. Intracellular routing in breast cancer cells of streptavidin-conjugated trastuzumab Fab fragments linked to biotinylated doxorubicin-functionalized metal chelating polymers.
Liu P; Cai Z; Kang JW; Boyle AJ; Adams J; Lu Y; Ngo Ndjock Mbong G; Sidhu S; Reilly RM; Winnik MA
Biomacromolecules; 2014 Mar; 15(3):715-25. PubMed ID: 24506198
[TBL] [Abstract][Full Text] [Related]
11. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM
J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548
[TBL] [Abstract][Full Text] [Related]
12. Construction of a novel chimera consisting of a chelator-containing Tat peptide conjugated to a morpholino antisense oligomer for technetium-99m labeling and accelerating cellular kinetics.
Zhang YM; Tung CH; He J; Liu N; Yanachkov I; Liu G; Rusckowski M; Vanderheyden JL
Nucl Med Biol; 2006 Feb; 33(2):263-9. PubMed ID: 16546682
[TBL] [Abstract][Full Text] [Related]
13. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
[TBL] [Abstract][Full Text] [Related]
14. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
15. Multimodality nuclear and fluorescence tumor imaging in mice using a streptavidin nanoparticle.
Liang M; Liu X; Cheng D; Liu G; Dou S; Wang Y; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2010 Jul; 21(7):1385-8. PubMed ID: 20557066
[TBL] [Abstract][Full Text] [Related]
16. Three-step tumor imaging with biotinylated monoclonal antibody, streptavidin and 111In-DTPA-biotin.
Nakamoto Y; Saga T; Sakahara H; Yao Z; Zhang M; Sato N; Zhao S; Nakada H; Yamashina I; Konishi J
Nucl Med Biol; 1998 Feb; 25(2):95-9. PubMed ID: 9468022
[TBL] [Abstract][Full Text] [Related]
17. Controlled internalization of Her-2/ neu receptors by cross-linking for targeted delivery.
Zhu W; Okollie B; Artemov D
Cancer Biol Ther; 2007 Dec; 6(12):1960-6. PubMed ID: 18075296
[TBL] [Abstract][Full Text] [Related]
18. Effect of administration route and dose of streptavidin or biotin on the tumor uptake of radioactivity in intraperitoneal tumor with multistep targeting.
Zhang M; Yao Z; Sakahara H; Saga T; Nakamoto Y; Sato N; Zhao S; Nakada H; Yamashina I; Konishi J
Nucl Med Biol; 1998 Feb; 25(2):101-5. PubMed ID: 9468023
[TBL] [Abstract][Full Text] [Related]
19. 111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
Cornelissen B; Kersemans V; McLarty K; Tran L; Reilly RM
Cancer Biother Radiopharm; 2009 Apr; 24(2):163-73. PubMed ID: 19409037
[TBL] [Abstract][Full Text] [Related]
20. Increased streptavidin uptake in tumors pretargeted with biotinylated antibody using a conjugate of streptavidin-fab fragment.
Yao Z; Zhang M; Sakahara H; Saga T; Kobayashi H; Nakamoto Y; Toyama S; Konishi J
Nucl Med Biol; 1998 Aug; 25(6):557-60. PubMed ID: 9751423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
